Development and testing of prediction models for end stage kidney disease patient nonadherence to renal replacement treatment regimens utilizing big data and healthcare informatics

2015 ◽  
Author(s):  
Yue Jiao ◽  
Dan Geary ◽  
Sheetal Chaudhuri ◽  
Mahathi Mothali ◽  
Terry Ketchersid ◽  
...  
Keyword(s):  
Big Data ◽  
Kidney Disease ◽  
Prediction Models ◽  
Disease Patient ◽  
Healthcare Informatics ◽  
End Stage Kidney Disease ◽  
Treatment Regimens ◽  
Replacement Treatment ◽  
Patient Nonadherence ◽  
End Stage

The impact of artificial intelligence and big data on end-stage kidney disease treatments

2021 ◽  
pp. 115076
Author(s):  
Covadonga Díez-Sanmartín ◽  
Antonio Sarasa-Cabezuelo ◽  
Amado Andrés Belmonte
Keyword(s):  
Artificial Intelligence ◽  
Big Data ◽  
Kidney Disease ◽  
End Stage Kidney Disease ◽  
End Stage ◽  
The Impact

scholarly journals The Need for Accurate Risk Prediction Models for Road Mapping, Shared Decision Making and Care Planning for the Elderly with Advanced Chronic Kidney Disease

PRILOZI ◽  
2016 ◽  
Vol 37 (2-3) ◽  
pp. 33-42 ◽  
Author(s):  
Marijke Stryckers ◽  
Evi V Nagler ◽  
Wim Van Biesen
Keyword(s):  
Chronic Kidney Disease ◽  
Decision Making ◽  
Kidney Disease ◽  
Shared Decision Making ◽  
Risk Prediction ◽  
Prediction Models ◽  
Shared Decision ◽  
End Stage Kidney Disease ◽  
Risk Prediction Models ◽  
End Stage

AbstractAs people age, chronic kidney disease becomes more common, but it rarely leads to end-stage kidney disease. When it does, the choice between dialysis and conservative care can be daunting, as much depends on life expectancy and personal expectations of medical care. Shared decision making implies adequately informing patients about their options, and facilitating deliberation of the available information, such that decisions are tailored to the individual’s values and preferences. Accurate estimations of one’s risk of progression to end-stage kidney disease and death with or without dialysis are essential for shared decision making to be effective. Formal risk prediction models can help, provided they are externally validated, well-calibrated and discriminative; include unambiguous and measureable variables; and come with readily applicable equations or scores. Reliable, externally validated risk prediction models for progression of chronic kidney disease to end-stage kidney disease or mortality in frail elderly with or without chronic kidney disease are scant. Within this paper, we discuss a number of promising models, highlighting both the strengths and limitations physicians should understand for using them judiciously, and emphasize the need for external validation over new development for further advancing the field.

scholarly journals Accelerated extensive mitral valve calcification in a young end-stage kidney disease patient

2020 ◽  
Vol 41 (45) ◽  
pp. 4361-4361
Author(s):  
Saarwaani Vallabhajosyula ◽  
Sameh M Said ◽  
Anna S Kitzmann ◽  
Hector I Michelena
Keyword(s):  
Mitral Valve ◽  
Kidney Disease ◽  
Disease Patient ◽  
End Stage Kidney Disease ◽  
Valve Calcification ◽  
End Stage ◽  
Mitral Valve Calcification

scholarly journals Importance of AST-120 (Kremezin®) Adherence in a Chronic Kidney Disease Patient with Diabetes

2018 ◽  
Vol 8 (2) ◽  
pp. 107-111 ◽  
Author(s):  
Yasuhiko Tomino ◽  
Atsuko Hisada-Urita ◽  
Takuto Seki ◽  
Tomonari Watanabe ◽  
Reo Kanda ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Serum Creatinine ◽  
Kidney Function ◽  
Japanese Society ◽  
Disease Patient ◽  
Insulin Injection ◽  
Adult Case ◽  
End Stage Kidney Disease ◽  
End Stage

We report herein an adult case of chronic kidney disease (CKD) associated with diabetes. The patient had been treated with insulin injection for diabetes 10 years ago. At the time of his first visit to our division for further examinations, we diagnosed him as CKD: cause (C) diabetes; glomerular filtration rate (GFR) (G) G5 (estimated [e] GFR, 10.2 mL/min/1.73 m2; serum creatinine of 4.90 mg/dL); and albuminuria (A) A3 (2.62 g/gCr) by the Japanese Society of Nephrology (JSN) CGA classification. Because he had complained of severe constipation and kidney function, i.e., eGFR was not improved by previous medications, we added on a minimal dosage (2 g/day) of AST-120 (Kremezin®; ordinary dose 6 g/day). After 3 months of AST-120 therapy, eGFR was increased to 17.8 mL/min/1.73 m2 (serum creatinine of 2.90–2.72 mg/dL). Although the patient used some laxative products, he could not continue to take Kremezin and completely stopped 8 months after starting this drug. Kidney function then abruptly declined and progressed to end-stage kidney disease (ESKD). In June 2017, he was introduced to hemodialysis. It appears that the adherence of Kremezin is very important for inhibiting the progression to ESKD for patients with CKD with diabetes.

Myoglobin Elimination in End Stage Kidney Disease Patients on Renal Replacement Treatment

1993 ◽  
Vol 16 (9) ◽  
pp. 659-661 ◽  
Author(s):  
V. Stefanović ◽  
M. Bogićević ◽  
M. Mitić
Keyword(s):  
Peritoneal Dialysis ◽  
Kidney Disease ◽  
Serum Levels ◽  
Hemodialysis Patients ◽  
Peritoneal Membrane ◽  
End Stage Kidney Disease ◽  
Replacement Treatment ◽  
End Stage ◽  
Hemodialysis Membrane ◽  
Serum Myoglobin

Increased serum myoglobin levels were previously found in patients with chronic renal failure. In this report we have studied the effects of dialysis on myoglobin elimination in patients on CARD, IPD, cuprophan and polyacrylonitrile (PAN) membrane hemodialysis. Peritoneal dialysis removed a significant amount of myoglobin, CAPD 480 ± 65 μg/day, IPD 270 ± 25 μg/12 h treatment, while with cuprophan dialysis none, and with PAN dialysis only an insignificant amount of myoglobin. The serum myoglobin levels were 250 ± 18 and 264 ± 14 μg/l on cuprophan and a 3 month dialysis on PAN membrane, respectively. Markedly increased serum levels were also found in CAPD and IPD patients on peritoneal dialysis, 227 ± 25 and 286 ± 32 μg/l respectively. This study has shown that there is an increased serum myoglobin concentration in end-stage kidney disease patients on dialysis. Although peritoneal membrane is permeable to myoglobin, a relatively small amount is removed, and the serum level in CAPD and IPD patients was not significantly different from the serum myoglobin concentration in hemodialysis patients. Furthermore myoglobin could not be removed by hemodialysis membrane and an analysis of its important extrarenal catabolism level points were analyzed.

scholarly journals Therapeutic Challenges to End-Stage Kidney Disease in a Patient with Tetralogy of Fallot

2015 ◽  
Vol 8 ◽  
pp. CCRep.S32121 ◽  
Author(s):  
Ken Ohara ◽  
Tetsu Akimoto ◽  
Takuya Miki ◽  
Naoko Otani ◽  
Taro Sugase ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Tetralogy Of Fallot ◽  
Clinical Course ◽  
Disease Patient ◽  
End Stage Kidney Disease ◽  
Appetite Loss ◽  
Dialysis Treatment ◽  
Complex Processes ◽  
End Stage ◽  
Available Information

In this report, we describe the case of an end-stage kidney disease patient with tetralogy of Fallot (TOF). A 33-year-old female with TOF was admitted to our hospital with complaints of general fatigue and appetite loss probably due to uremic milieu. She was ultimately treated with peritoneal dialysis (PD) with a favorable clinical course. TOF patients with chronic kidney disease are not exceptional, although the currently available information regarding the association between TOF and renal failure severe enough to require dialysis treatment is limited. We also discuss the complex processes of how and why PD was selected as a mode of chronic renal replacement therapy in this case.

Sign in / Sign up

Export Citation Format

Share Document